Sep 04, 2019 / 01:40PM GMT
Yanan Zhu - Wells Fargo Securities, LLC, Research Division - Associate Analyst
I think we should get started. My name is Yanan Zhu, and I'm a member of the biotech equity research team here at Wells Fargo. It is my great pleasure to introduce our next presenting company, Moderna, and their CFO, Lorence Kim. As you might know, Moderna is in a very exciting space of mRNA therapeutics, and the company has a very big pipeline with a lot going on. So without any further ado, Lorence.
Lorence H. Kim - Moderna, Inc. - CFO
Great, thank you. It's my pleasure to present the Moderna story. I'll try to do so in about the next 20 minutes. Let me begin by just noting that I'll be making forward-looking statements, as you can see here. And I won't read this whole slide to you. Messenger RNA, so Moderna is entirely focused on mRNA as a new potential drug class. We believe quite strongly in the opportunity represented by this ability to deliver mRNA into cells and to have those cells make all sorts of proteins, including proteins that were previously not accessible to prior
Moderna Inc at Wells Fargo Healthcare Conference Transcript
Sep 04, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers